Search
Aprobarbital
go.drugbank.com/drugs/DB01352ExperimentalIllicitAprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. … A primary treatment indicated for the use of aprobarbital was subsequently insomnia.
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33359] In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and [ritonavir], for the treatment of certain patients with … [L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.
Tretinoin
go.drugbank.com/drugs/DB00755ApprovedInvestigationalNutraceutical[A257474] It is an oxidation product in the physiological pathway of vitamin A metabolism. … [A257689] In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L.
Synonyms: all-(E)-Retinoic acid, (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acidInternational brands: Stieva-ABazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalBazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. … It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy.
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalIt is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily … A and one from subfamily B (A05 and B01, respectively).
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5MLCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis. … This chemical modification significantly enhances its affinity for FcγRIII receptors on immune effector cells.
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnIt is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR).
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK … It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience. … with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022.